GIP receptor
One incretin-receptor arm contributes to glucose-dependent metabolic signaling.
Retatrutide
Promising trial results do not make an investigational drug an approved product
A triple-receptor investigational peptide with major Phase 2 results and no approved product or brand
Retatrutide (LY3437943) is an investigational agonist of GIP, GLP-1, and glucagon receptors being studied for obesity and related metabolic conditions. It is not an FDA-approved drug. Published phase 2 results are substantial but come from defined trial products, populations, monitoring, and protocols; they do not validate products sold outside clinical trials.
Evidence audited · Sources and limitations shown beside each claim
Mechanism and certainty
How researchers think it works
Retatrutide is designed as one molecule that activates three class-B G-protein-coupled receptors. Receptor pharmacology is established; how each arm contributes to each clinical outcome remains an active research question.
GLP-1 receptor
A second incretin-receptor arm overlaps with appetite and glucose-regulation pathways studied across this drug class.
Glucagon receptor
The third receptor distinguishes retatrutide from single- and dual-agonist programs, but trial outcomes should not be reduced to one receptor narrative.
Evidence boundary: Phase 2 outcomes establish measured group effects in trial populations; they do not establish approval, every long-term mechanism, or the identity of online products.
Study results, visualized
What the measured results show
1 mg−8.7%
4 mg−17.1%
8 mg−22.8%
12 mg−24.2%
Placebo−2.1%
Sponsor-funded Phase 2 trial with defined eligibility, escalation, monitoring, and trial material; not a dosing guide or individual forecast.
Retatrutide groups−42.9% to −82.4%
Placebo+0.3%
The bar uses the largest reported group reduction to visualize the range. This imaging biomarker does not establish prevention of liver-related clinical events.
Product and regulatory distinctions
A compound name is not one interchangeable set of instructions. Product, formulation, indication, labeling, and jurisdiction matter.
Retatrutide (LY3437943)
Investigational; no FDA-approved retatrutide product or prescribing information exists. Phase 3 trials are registered and ongoing or recently completed, depending on the study.
Current sourceProducts sold online as retatrutide
A seller's label does not establish that a product is the sponsor's clinical-trial material, has the stated identity or purity, or is FDA-approved.
Current sourceMolecular identity
What the molecule actually is
- Classification
- Single investigational peptide agonist engineered for GIP, GLP-1, and glucagon receptors
- Chain
- Modified peptide with a lipid side chain; use the NIH/NCATS substance record for the authoritative structure
Vendor sequences frequently disagree about residues, counterions, and molecular weight. Dosi therefore links the NIH/NCATS GSRS identity and molecular diagram instead of reproducing an unverified seller sequence.
What the name alone cannot tell you
- A lipid side chain is attached through a linker to support prolonged exposure.
- LY3437943 is a development code, not a brand name.
Use in the real world
How many people take retatrutide?
No defensible general-use estimate exists; legitimate exposure is through research studies.
Retatrutide is investigational and cannot lawfully be used in compounding. Registered-trial enrollment documents research participation, while seller volume, searches, social posts, or adverse-event reports cannot be converted into a user count.
Claim-by-claim evidence map
Each finding is tied to the population and product actually studied. Trial results are not personal predictions.
Retatrutide produced dose-dependent weight reduction in a phase 2 obesity trial.
- Population
- 338 adults with obesity, or overweight plus a weight-related condition, in a 48-week randomized placebo-controlled trial.
- Finding
- Mean weight change at 48 weeks ranged from -8.7% in the 1-mg group to -24.2% in the 12-mg group, compared with -2.1% with placebo.
- Limits
- This was a sponsor-funded phase 2 study with defined eligibility and monitoring. Results do not predict an individual's outcome or establish approval, long-term benefit-risk, or equivalence of non-trial products.
Retatrutide improved glycemic measures in a phase 2 type 2 diabetes trial.
- Population
- Adults with type 2 diabetes in a 36-week randomized, double-blind, placebo- and active-controlled U.S. trial.
- Finding
- The study reported dose-dependent HbA1c and body-weight reductions, with higher-dose groups compared against placebo and dulaglutide.
- Limits
- Phase 2 efficacy does not replace cardiovascular, longer-term safety, or confirmatory evidence and does not authorize clinical use outside a trial.
A phase 2 substudy found large reductions in liver fat among participants with elevated baseline liver fat.
- Population
- 98 participants from the obesity trial with at least 10% liver fat at baseline.
- Finding
- At 24 weeks, mean relative liver-fat change ranged from -42.9% to -82.4% across retatrutide groups versus +0.3% with placebo.
- Limits
- This was a small substudy using an imaging biomarker; it does not establish prevention of cirrhosis, liver-related events, or benefit in people outside the studied population.
Gastrointestinal events and increased heart rate were observed in the phase 2 obesity program.
- Population
- Participants in the 48-week phase 2 obesity trial.
- Finding
- Gastrointestinal events were the most common adverse events and were dose-related; dose-dependent heart-rate increases peaked at 24 weeks and later declined.
- Limits
- A phase 2 trial is not large or long enough to characterize every uncommon, delayed, or population-specific risk.
What this evidence does not answer
- No FDA-approved retatrutide label yet defines indications, contraindications, warnings, dosing, manufacturing controls, or postmarketing safety.
- Long-term cardiovascular, pancreatic, gallbladder, thyroid, hepatic, and other benefit-risk questions require the completed phase 3 program and regulatory review.
- Clinical-trial results cannot validate the identity, sterility, purity, dose accuracy, or safety of products sold as research-grade or compounded retatrutide.
Useful information to organize between visits
- Whether access is through a registered clinical trial and the trial identifier
- The exact investigational product documentation—not a seller's use of the name retatrutide
- Symptoms, laboratory results, and study visits recorded through the trial team
- Every medicine, supplement, and experimental product disclosed to trial investigators
- Questions directed to the study clinician or pharmacist rather than online dosing discussions
Questions to bring to a clinician or pharmacist
- 1.Is there an appropriate registered clinical trial for which I might qualify?
- 2.How does investigational status differ from FDA approval and routine prescribing?
- 3.Which established treatments have approved labeling for my condition now?
- 4.What should a trial participant report promptly to the research team?
How to use this research profile
This page aggregates regulatory documents and published human research. Its claims, citations, populations, and limitations received an independent editorial evidence check. Last editorial audit: . It has not been medically reviewed by a clinician. It provides general education, not diagnosis, treatment, dosing instructions, or advice for an individual. Use the product-specific official information and consult a qualified clinician or pharmacist for personal decisions.
Primary sources
- Retatrutide substance record (NOP2Y096GV)NIH/NCATS Global Substance Registration System · Published Updated 2026 · Accessed July 13, 2026
- Structural insights into triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutideNature Communications via PubMed · Published 2024 · Accessed July 13, 2026
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialThe New England Journal of Medicine via PubMed · Published 2023 · Accessed July 12, 2026
- Retatrutide for people with type 2 diabetes: a randomized phase 2 trialThe Lancet via PubMed · Published 2023 · Accessed July 12, 2026
- Retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialNature Medicine via PubMed · Published 2024 · Accessed July 12, 2026
- TRIUMPH-1: Retatrutide in participants with obesity or overweightClinicalTrials.gov · Published 2023 · Accessed July 12, 2026
- TRIUMPH-3: Retatrutide in participants with obesity and cardiovascular diseaseClinicalTrials.gov · Published 2023 · Accessed July 12, 2026
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossU.S. Food and Drug Administration · Published 2026 · Accessed July 12, 2026
Turn scattered notes into a useful treatment history
Dosi organizes timing, locations, symptoms, reminders, and questions for your next appointment. It does not prescribe or replace your care team.
Start tracking free